AlloVir To Cut 95% of Workforce After Discontinuing Trials
By Ben Glickman AlloVir will cut about 95% of its current employee base after scrapping three late-stage clinical trials. The cell-therapy developer said in...
Stay updated with breaking news from Alvr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Ben Glickman AlloVir will cut about 95% of its current employee base after scrapping three late-stage clinical trials. The cell-therapy developer said in...
Bank of America cut shares of AlloVir (NASDAQ:ALVR – Free Report) from a buy rating to an underperform rating in a report published on Tuesday morning, Marketbeat reports. Several other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. cut shares of AlloVir from an overweight rating to an underweight […]
SVB Leerink downgraded shares of AlloVir (NASDAQ:ALVR – Free Report) from an outperform rating to a market perform rating in a report published on Friday, MarketBeat reports. ALVR has been the topic of several other research reports. Piper Sandler downgraded shares of AlloVir from an overweight rating to a neutral rating in a research note […]
SVB Leerink lowered shares of AlloVir (NASDAQ:ALVR – Free Report) from an outperform rating to a market perform rating in a report published on Friday, MarketBeat reports. A number of other analysts have also recently commented on the stock. Piper Sandler cut shares of AlloVir from an overweight rating to a neutral rating in a […]
Piper Sandler lowered shares of AlloVir (NASDAQ:ALVR – Free Report) from an overweight rating to a neutral rating in a report issued on Friday, MarketBeat reports. Separately, JPMorgan Chase & Co. lowered AlloVir from an overweight rating to an underweight rating in a report on Friday. One investment analyst has rated the stock with a […]